Intranasal inoculation of an MVA-based vaccine induces IgA and protects the respiratory tract of hACE2 mice from SARS-CoV-2 infection

Current vaccines have greatly diminished the severity of the COVID-19 pandemic, even though they do not entirely prevent infection and transmission, likely due to insufficient immunity in the upper respiratory tract. Here, we compare intramuscular and intranasal administration of a live, replication...

Full description

Saved in:
Bibliographic Details
Published inProceedings of the National Academy of Sciences - PNAS Vol. 119; no. 24; p. e2202069119
Main Authors Americo, Jeffrey L, Cotter, Catherine A, Earl, Patricia L, Liu, Ruikang, Moss, Bernard
Format Journal Article
LanguageEnglish
Published United States National Academy of Sciences 14.06.2022
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Current vaccines have greatly diminished the severity of the COVID-19 pandemic, even though they do not entirely prevent infection and transmission, likely due to insufficient immunity in the upper respiratory tract. Here, we compare intramuscular and intranasal administration of a live, replication-deficient modified vaccinia virus Ankara (MVA)-based Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) spike (S) vaccine to raise protective immune responses in the K18-hACE2 mouse model. Using a recombinant MVA expressing firefly luciferase for tracking, live imaging revealed luminescence of the respiratory tract of mice within 6 h and persisting for 3 d following intranasal inoculation, whereas luminescence remained at the site of intramuscular vaccination. Intramuscular vaccination induced S-binding-Immunoglobulin G (IgG) and neutralizing antibodies in the lungs, whereas intranasal vaccination also induced Immunoglobulin A (IgA) and higher levels of antigen-specific CD3 CD8 IFN-γ T cells. Similarly, IgG and neutralizing antibodies were present in the blood of mice immunized intranasally and intramuscularly, but IgA was detected only after intranasal inoculation. Intranasal boosting increased IgA after intranasal or intramuscular priming. While intramuscular vaccination prevented morbidity and cleared SARS-CoV-2 from the respiratory tract within several days after challenge, intranasal vaccination was more effective as neither infectious virus nor viral messenger (m)RNAs were detected in the nasal turbinates or lungs as early as 2 d after challenge, indicating prevention or rapid elimination of SARS-CoV-2 infection. Additionally, we determined that neutralizing antibody persisted for more than 6 mo and that serum induced to the Wuhan S protein neutralized pseudoviruses expressing the S proteins of variants, although with less potency, particularly for Beta and Omicron.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Author contributions: J.L.A., C.A.C., P.L.E., and B.M. designed research; J.L.A., C.A.C., and P.L.E. performed research; C.A.C. and R.L. contributed new reagents/analytic tools; J.L.A., C.A.C., P.L.E., and B.M. analyzed data; J.L.A. prepared figures; and B.M. wrote the paper.
Contributed by Bernard Moss; received February 6, 2022; accepted April 15, 2022; reviewed by Akiko Iwasaki and Kanta Subbarao
1Present address: School of Basic Medical Sciences, Shandong University, 250061 Ji’nan, China.
ISSN:0027-8424
1091-6490
DOI:10.1073/pnas.2202069119